NovoCure Past Earnings Performance

Past criteria checks 0/6

NovoCure's earnings have been declining at an average annual rate of -58.1%, while the Medical Equipment industry saw earnings growing at 11.4% annually. Revenues have been growing at an average rate of 8.3% per year.

Key information

-58.1%

Earnings growth rate

-56.9%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate8.3%
Return on equity-46.6%
Net Margin-30.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

NovoCure Limited: A Post Q2 Analysis

Jul 26

NovoCure Limited Q1 Earnings: Core Business Accelerating

May 03

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

Apr 08
NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

NovoCure: Sell The METIS-Inspired Rally

Mar 28

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Mar 03
Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

NovoCure: Stay Cautious Amid Positive Signs

Jan 19

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Nov 16
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Aug 13
Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

May 15
Is NovoCure (NASDAQ:NVCR) A Risky Investment?

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Apr 24
A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Feb 10
Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Jan 16
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

NovoCure: See Past Market Myopia And Buy The Dip

Sep 27

Novocure creates new CNS focused franchise to renew growth in brain cancer business

Sep 21

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Sep 09
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Sep 09

NovoCure Q2 2022 Earnings Preview

Jul 27

Revenue & Expenses Breakdown

How NovoCure makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:NVCR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24550-169382212
31 Mar 24526-193387213
31 Dec 23509-207387221
30 Sep 23504-197380224
30 Jun 23508-174354222
31 Mar 23522-141331224
31 Dec 22538-93306206
30 Sep 22543-82289208
30 Jun 22545-68279204
31 Mar 22538-59269198
31 Dec 21535-58263201
30 Sep 21546-27253188
30 Jun 21545-5246173
31 Mar 2152712232153
31 Dec 2049420225132
30 Sep 2045019216112
30 Jun 204091220698
31 Mar 20380919787
31 Dec 19351-718579
30 Sep 19322-2717470
30 Jun 19294-4116665
31 Mar 19269-5515857
31 Dec 18248-6415151
30 Sep 18232-5914346
30 Jun 18217-5913742
31 Mar 18194-6413140
31 Dec 17177-6212338
30 Sep 17154-7311537
30 Jun 17125-9511237
31 Mar 17105-11410839
31 Dec 1683-13210741
30 Sep 1665-14310844
30 Jun 1652-1359644
31 Mar 1641-1248545
31 Dec 1533-1127344
30 Sep 1525-1026044
30 Jun 1520-945343
31 Mar 1518-864941
31 Dec 1415-814540
31 Dec 1310-773335

Quality Earnings: NVCR is currently unprofitable.

Growing Profit Margin: NVCR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NVCR is unprofitable, and losses have increased over the past 5 years at a rate of 58.1% per year.

Accelerating Growth: Unable to compare NVCR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NVCR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.2%).


Return on Equity

High ROE: NVCR has a negative Return on Equity (-46.63%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies